Intra‐ and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts

Intra‐ and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts

Abstract The development of targeted inhibitors, like vemurafenib, has greatly improved the clinical outcome of BRAFV600E metastatic melanoma. However, resistance to such compounds represents a formidable problem. Using whole‐exome sequencing and functional analyses, we have investigated the nature...

Full description

Bibliographic Details
Main Authors: Kristel Kemper, Oscar Krijgsman, Paulien Cornelissen‐Steijger, Aida Shahrabi, Fleur Weeber, Ji‐Ying Song, Thomas Kuilman, Daniel J Vis, Lodewyk F Wessels, Emile E Voest, Ton NM Schumacher, Christian U Blank, David J Adams, John B Haanen, Daniel S Peeper
Format: Article
Language:English
Published: Springer Nature 2015-06-01
Series:EMBO Molecular Medicine
Subjects:
Melanoma
drug resistance
tumor heterogeneity
patient‐derived xenografts
Online Access:https://doi.org/10.15252/emmm.201404914

Internet

https://doi.org/10.15252/emmm.201404914

Similar Items